The FDA has extended the review period for Karyopharm Therapeutics' new drug application for selinexor for patients with penta-refractory multiple myeloma, with its action date moved from April 6 to July 6. The delay is based on a recommendation made by the agency's Oncologic Drugs Advisory Committee opposing selinexor's accelerated approval.
Earn a free year of digital access to NYT Cooking Get cooking with The New York Times. You'll receive unlimited access to over 19,000 Times-tested recipes, helpful guides, and the wit, wisdom and inspiration of Times food writers. Refer SmartBrief to 5 colleagues and enjoy a free year of unlimited access to NYT Cooking. Your Referral Link:smartbrief.com/BIO/?referrerId=eSriBJbAIQ&campaign=ad_referral_NYTcook
Researchers conducting a small Phase I trial found that an experimental drug could be an antidote to the antiplatelet drug Brilinta, or ticagrelor, showing use of PhaseBio Pharmaceuticals' PB2452 resulted in a reversal of ticagrelor's effects within five minutes that lasted for over 20 hours. The findings were reported in The New England Journal of Medicine.
The European Medicines Agency has begun operating from its temporary Amsterdam headquarters and is expected to house almost 350 staff members there as of today. The agency expects to lose about a quarter of its employees due to the relocation.
CARsgen Therapeutics announced that clearance from the Chinese National Medical Products Administration for its investigational new drug application for CT053 will allow the firm to begin clinical testing for its chimeric antigen receptor T-cell therapy to treat relapsed or refractory multiple myeloma in China. CARsgen also plans to submit an IND for CT053 for approval by US regulators this year.
The first patient has been dosed in a Phase IIa study for Lexicon Pharmaceuticals' Xermelo, or telotristat ethyl, for the treatment of biliary tract cancer. The company expects to gather topline data next year.
The American Heart Association and the American College of Cardiology have revised their recommendations on the use of aspirin for those never diagnosed for heart disease, presenting the updated primary prevention guidelines during a recent ACC conference. The new guidance was based on findings from newer studies that showed an increased risk for bleeding by aspirin users, particularly gastrointestinal bleeding, although the drug is still recommended for prevention of heart attacks in those previously diagnosed with cardiovascular illnesses.
Merck KGaA and Iktos agreed to collaborate to research and develop therapies using the latter's artificial intelligence technology. The technology automatically designs virtual novel molecules with desired activities for treating a particular disease.
The Nikon Instruments Research Grade Microscope Systems Program is available to BIO members and offers a wide selection of research instrumentation and digital imaging solutions for microscopy for direct purchase. Through the BIO-Nikon program, members receive exclusive discounts and benefits. Learn more.
Finalized rules on biotech foods, including agricultural and marine products, are expected from a Japanese health ministry panel today. The rules would require companies to inform the government about the kind of biotech food they plan to distribute and could allow sales of biotech foods in Japan as early as this summer.
BIO has partnered with Clean Harbors, a worldwide leader in waste management and environmental services, to offer members a full range of hazardous and nonhazardous materials management and disposal services with deep discounts: 35%-40% off list on disposal, 15%-20% off list on transportation and materials, and 35% off list price on labor charges. In addition, the BIO-Clean Harbors program offers full online tracking, free site visits to assure compliance with state and federal laws, and staff training support at no additional charge. Learn more!
Life doesn't begin when you lose weight. Big dreams can be planned for and achieved in the bodies we have today, regardless of size or age.
Deb Malkin, one of at least 20 plus-size women who hiked Mount Kilimanjaro together from March 2 to 10
March is Women's History Month
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at firstname.lastname@example.org.